MetaVia Inc. Files 8-K, Former Names Revealed
Ticker: MTVA · Form: 8-K · Filed: May 21, 2025 · CIK: 1638287
| Field | Detail |
|---|---|
| Company | Metavia INC. (MTVA) |
| Form Type | 8-K |
| Filed Date | May 21, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-update, name-change
TL;DR
MetaVia Inc. (formerly NeuroBo/Gemphire) filed an 8-K on 5/21/25 with updated HQ info.
AI Summary
On May 21, 2025, MetaVia Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 545 Concord Avenue, Suite 210, Cambridge, MA 02138. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and Gemphire Therapeutics Inc.
Why It Matters
This filing provides updated corporate information and historical name changes for MetaVia Inc., which may be relevant for investors tracking the company's evolution.
Risk Assessment
Risk Level: low — The filing is a routine corporate update and does not contain significant financial or operational news.
Key Players & Entities
- MetaVia Inc. (company) — Registrant
- NeuroBo Pharmaceuticals, Inc. (company) — Former Company Name
- Gemphire Therapeutics Inc. (company) — Former Company Name
- 545 Concord Avenue, Suite 210, Cambridge, MA 02138 (location) — Principal Executive Offices
FAQ
What is the exact date of the report?
The date of the report is May 21, 2025.
What is the company's current name?
The company's current name is MetaVia Inc.
What were the company's previous names?
The company was formerly known as NeuroBo Pharmaceuticals, Inc. and Gemphire Therapeutics Inc.
Where are MetaVia Inc.'s principal executive offices located?
MetaVia Inc.'s principal executive offices are located at 545 Concord Avenue, Suite 210, Cambridge, Massachusetts 02138.
What is the company's IRS Employer Identification No.?
The company's IRS Employer Identification No. is 47-2389984.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 21, 2025 regarding MetaVia Inc. (MTVA).